EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder

Abd El Kader Ait Tayeb iD, Edouard-Jules Laforgue iD, Benoit Schreck, Marie Grall-Bronnec, Jean-Benoit Hardouin, Juliette Leboucher, OPAL Group, Caroline Victorri-Vigneau, Céline Verstuyft

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Abd El Kader Ait Tayeb und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de…. Hauptthemen laut MEDLINE: Methadone, Catechol O-Methyltransferase, Opioid-Related Disorders, Receptors, Opioid, mu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives, Université Paris 13.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Opioid use disorder (OUD) is an emerging and global public health concern, and its management remains inadequate, notably due to a lack of biomarkers, except for the CYP2B6 genetic polymorphisms.

Objectives

Hence, the aim of this study was to assess the influence of genetic polymorphisms of ABCB1, SLC22A1, COMT, and OPRM1 on biological parameters and clinical response in patients receiving methadone maintenance treatment (MMT).

Methods

A subgroup of 72 patients treated by MMT was genotyped for ABCB1 (rs1045642; rs2032582), SLC22A1 (rs12208357; rs72552763; rs113569197), COMT (rs4680), and OPRM1 (rs1799971) from Opioid PhArmacoLogy (OPAL), a clinical survey of patients suffering from OUD. Associations of these polymorphisms and both clinical and pharmacological (plasma methadone levels) responses were investigated.

Results

All polymorphisms tested were not associated with (R,S)‐methadone concentrations/doses (concentrations relative to doses), (R)‐methadone concentrations/doses nor (S)‐methadone concentrations/doses in bivariate analyses with codominant and recessive models. Also, polymorphisms tested were not related to clinical response (opiate cessation) during MMT in treated patients. The main limitations of our study were the sample size and the absence of polygenic analyses.

Conclusion

This study found no evidence to support the use of genotyping for polymorphisms in the ABCB1, SLC22A1, COMT, and OPRM1 genes in a clinical setting for the management of MMT in OUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethadoneCatechol O-MethyltransferaseOpioid-Related DisordersReceptors, Opioid, muOpiate Substitution TreatmentOrganic Cation Transporter 1HumansMaleFemaleAdultATP Binding Cassette Transporter, Subfamily BGenotypeMiddle AgedPolymorphism, Single NucleotideAnalgesics, Opioid

Stichwörter der Autor:innen

methadone maintenance treatmentopioid use disorderpharmacodynamic targetspharmacogeneticspharmacokinetic targets

Substanzen

MethadoneABCB1 protein, humanOPRM1 protein, humanCatechol O-MethyltransferaseCOMT protein, humanReceptors, Opioid, muATP Binding Cassette Transporter, Subfamily BOrganic Cation Transporter 1Analgesics, Opioid

Autor:innen und Institutionen

  • Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France.
  • Inserm, Physiologie et Physiopathologie Endocriniennes, Université Paris-Saclay, Le Kremlin-Bicêtre, 94276, France.
  • CHU Nantes, CHU Tours, INSERM, MethodS in Patients-Centered Outcomes and HEalth Research, SPHERE, Nantes Université, Univ Tours, Nantes, 44000, France.
  • CHU Nantes, Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, Nantes, 44000, France.
  • UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, Nantes, 44000, France.
  • CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France.

ORCID-Profile: Abd El Kader Ait Tayeb, Edouard-Jules Laforgue

Förderung

  • Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives
  • Université Paris 13

Zitieren

APA

Ait Tayeb, A. E. K., Laforgue, E. J., Schreck, B., Grall-Bronnec, M., Hardouin, J. B., Leboucher, J., OPAL Group, Victorri-Vigneau, C., & Verstuyft, C. (2025). ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70013

Vancouver

Ait Tayeb AEK, Laforgue EJ, Schreck B, Grall-Bronnec M, Hardouin JB, Leboucher J, et al. ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70013

BibTeX
@article{AitTayeb2025,
  author = {Ait Tayeb, Abd El Kader and Laforgue, Edouard-Jules and Schreck, Benoit and Grall-Bronnec, Marie and Hardouin, Jean-Benoit and Leboucher, Juliette and OPAL Group, OPAL Group and Victorri-Vigneau, Caroline and Verstuyft, Céline},
  title = {ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70013}
}
Kostenlos starten →